Maturation Matrix for Cardiomyocyte Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The use of human induced pluripotent stem cells (hiPSCs) for drug testing is limited by the challenge of maturation, as immature cardiomyocytes (CMs) differ significantly from their adult counterparts, leading to false positives and false negatives in drug effect assessments.
Innovation Solution
A method involving the measurement of transmembrane voltage and intracellular calcium concentration in immature CMs, followed by data inversion and maturation modeling to simulate the effects of drugs on mature CMs, allowing for the determination of drug effects on mature cardiomyocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If immature cardiomyocytes are used for drug testing, then the ease of obtaining and culturing cells is improved, but the reliability of drug effect assessment deteriorates due to significant differences from adult cardiomyocytes
Solution Approach 1:
The patent creates a computational copy of the mature cardiomyocyte by building a mathematical model that replicates the electrophysiological behavior of adult cells. The model incorporates ion channel dynamics, membrane potential changes, and calcium handling to produce a virtual representation that accurately mimics mature cell responses to drugs, allowing reliable assessment without using actual mature cells.
Solution Approach 2:
The patent transforms the immature cell data into mature cell predictions by systematically adjusting key parameters. The model modifies ion channel conductances, membrane capacitance, and other electrophysiological parameters to account for the developmental differences between immature and mature cardiomyocytes, thereby converting observations from easily cultured immature cells into accurate predictions for mature cell drug responses.
2Productivity
If immature cardiomyocytes are used for drug screening, then the productivity of drug development is improved, but the measurement precision of drug effects deteriorates due to false positives and false negatives
Solution Approach 1:
The computational model serves as a precise copy that preserves the electrophysiological characteristics of mature cardiomyocytes. By simulating action potentials, ion channel behaviors, and calcium transients in the virtual model, the system maintains measurement precision equivalent to using actual mature cells while working with immature cell data, thereby eliminating false positives and false negatives.
Solution Approach 2:
The patent replaces the physical biological system (mature cardiomyocytes) with a computational mathematical model. This substitution uses numerical simulations and algorithms to predict drug effects, replacing the need for physically culturing and testing on mature cells while maintaining or improving measurement precision through controlled computational experiments.
3Reliability
If mature cardiomyocytes are used for accurate drug effect assessment, then the reliability of results is improved, but the ease of manufacture and availability of cells deteriorates
Solution Approach 1:
The patent performs preliminary computational transformations by creating a maturation model that pre-calculates the differences between immature and mature cell behaviors. The system预先 establishes the parameter adjustments needed to simulate maturation, so when drug effects are measured on immature cells, the pre-prepared model can accurately translate these results to predict mature cell responses without requiring actual mature cells to be available.
Solution Approach 2:
The computational model acts as an intermediary between immature cell experiments and mature cell predictions. Rather than directly using mature cells or directly measuring immature cell responses, the model serves as a mediating layer that translates observations from immature cells into accurate predictions for mature cells, bridging the gap between availability and reliability.
Data Source
AI summary
The present invention provides a method for determining the effect of a drug on a mature cardiomyocyte. In some embodiments, the method comprises using transmembrane voltage and/or intracellular calcium data obtained from control immature cardiomyocytes and those that have been contacted with the drug to parameterize models of immature cardiomyocytes, then applying a maturation matrix to generate a mature cardiomyocyte model. The method is useful for, among other things, predicting whether a drug may have proarrhythmic properties and for determining whether a particular drug should be administered to a patient.